Fig. 3

TDRKH-AS1 could act as a ceRNA by binding to miR-134-5p. A The cellular localization of TDRKH-AS1 (labeled in red) in breast cancer (BC) cells was determined using RNA fluorescence in situ hybridization (FISH) assay. B Spearman correlation analysis revealed a significant negative correlation between TDRKH-AS1 and miR-134-5p in BC cells. C In silico prediction analysis suggested that miR-134-5p could potentially bind to TDRKH-AS1. D, E The interaction between TDRKH-AS1 and miR-134-5p was further confirmed using luciferase reporter assay and RNA immunoprecipitation (RIP) assay. F The knockdown of TDRKH-AS1 using siRNA resulted in a significant increase in the expression level of miR-134-5p in BC cells. G Receiver operating characteristic (ROC) curve analysis showed that miR-134-5p could be a potential discriminator between BC and normal tissues. H The results from the starBase database indicated that miR-134-5p expression was significantly downregulated in BC tissues compared to normal tissues. I RT-qPCR was used to detect the expression levels of miR-134-5p in clinical samples, and the results showed a significant difference in expression levels between BC and normal tissues. ^∗P < 0.05; ^∗∗P < 0.01